251 related articles for article (PubMed ID: 12531181)
1. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets.
Pray TR; Parlati F; Huang J; Wong BR; Payan DG; Bennett MK; Issakani SD; Molineaux S; Demo SD
Drug Resist Updat; 2002 Dec; 5(6):249-58. PubMed ID: 12531181
[TBL] [Abstract][Full Text] [Related]
2. Targeting E3 ubiquitin ligases for cancer therapy.
Sun Y
Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
[TBL] [Abstract][Full Text] [Related]
3. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
[TBL] [Abstract][Full Text] [Related]
4. E3 ubiquitin ligases as cancer targets and biomarkers.
Sun Y
Neoplasia; 2006 Aug; 8(8):645-54. PubMed ID: 16925947
[TBL] [Abstract][Full Text] [Related]
5. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
Kitagawa K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
[TBL] [Abstract][Full Text] [Related]
6. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
Uchida C; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
[TBL] [Abstract][Full Text] [Related]
7. E3 ubiquitin ligases in cancer and implications for therapies.
Wang D; Ma L; Wang B; Liu J; Wei W
Cancer Metastasis Rev; 2017 Dec; 36(4):683-702. PubMed ID: 29043469
[TBL] [Abstract][Full Text] [Related]
8. A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.
Satija YK; Bhardwaj A; Das S
Int J Cancer; 2013 Dec; 133(12):2759-68. PubMed ID: 23436247
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1-F-box interface.
Gorelik M; Orlicky S; Sartori MA; Tang X; Marcon E; Kurinov I; Greenblatt JF; Tyers M; Moffat J; Sicheri F; Sidhu SS
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3527-32. PubMed ID: 26976582
[TBL] [Abstract][Full Text] [Related]
10. Molecular targeting of E3 ligases--a therapeutic approach for cancer.
Lakshmanan M; Bughani U; Duraisamy S; Diwan M; Dastidar S; Ray A
Expert Opin Ther Targets; 2008 Jul; 12(7):855-70. PubMed ID: 18554154
[TBL] [Abstract][Full Text] [Related]
11. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Masumoto K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
[TBL] [Abstract][Full Text] [Related]
12. Role of E3 ubiquitin ligases in gastric cancer.
Hou YC; Deng JY
World J Gastroenterol; 2015 Jan; 21(3):786-93. PubMed ID: 25624711
[TBL] [Abstract][Full Text] [Related]
13. Targeting E3 Ubiquitin Ligases and Deubiquitinases in Ciliopathy and Cancer.
Shiromizu T; Yuge M; Kasahara K; Yamakawa D; Matsui T; Bessho Y; Inagaki M; Nishimura Y
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825105
[TBL] [Abstract][Full Text] [Related]
14. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
Daks AA; Melino D; Barlev NA
Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
[TBL] [Abstract][Full Text] [Related]
15. Overview of approaches for screening for ubiquitin ligase inhibitors.
Sun Y
Methods Enzymol; 2005; 399():654-63. PubMed ID: 16338387
[TBL] [Abstract][Full Text] [Related]
16. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
Liu L; Wong CC; Gong B; Yu J
Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
[TBL] [Abstract][Full Text] [Related]
17. Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.
Wang H; Lu Y; Wang M; Wu Y; Wang X; Li Y
J Mol Med (Berl); 2021 Feb; 99(2):193-212. PubMed ID: 33392633
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-Regulated Cell Proliferation and Cancer.
Pérez-Benavente B; Nasresfahani AF; Farràs R
Adv Exp Med Biol; 2020; 1233():3-28. PubMed ID: 32274751
[TBL] [Abstract][Full Text] [Related]
19. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
Yu Q; Xiong X; Sun Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419
[TBL] [Abstract][Full Text] [Related]
20. Targeted modulation of E3 ligases using engineered ubiquitin variants.
LeBlanc N; Mallette E; Zhang W
FEBS J; 2021 Apr; 288(7):2143-2165. PubMed ID: 32867007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
